NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440

Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440

1.1 Pegylated liposomal irinotecan, in combination with 5‑fluorouracil and leucovorin, is not recommended, within its marketing authorisation, for treating metastatic adenocarcinoma of the pancreas in adults whose disease has progressed after gemcitabine-based therapy.

1.2 This guidance is not intended to affect the position of patients whose treatment with pegylated liposomal irinotecan was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

https://www.nice.org.uk/guidance/ta440

Site by Devopa
© Copyright 2019 NHS. All rights reserved.